News and Trends 22 Sep 2022 Swiss scientists reduce resistance of dormant melanoma cells Small-molecule targeted therapies revolutionized the treatment of metastatic melanoma, provided that the tumors carry the mutations to respond to these treatments. However, despite an initial response that can be seen in a majority of patients, most of them will undergo relapse even after sometimes spectacular initial responses. These relapses are due to “dormant” persistent cells, […] September 22, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 22 Sep 2022 New study shows how prostate cancer may start Researchers at the University of East Anglia in the U.K. say they have made an important discovery about how prostate cancer may start to develop. A new study published in Molecular Oncology reveals that the prostate as a whole, including cells that appear normal, is different in men with prostate cancer. It suggests that tissue […] September 22, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Best in Biotech 21 Sep 2022 The 5 hottest biotech companies making waves in Israel Despite its small population, Israel hosts a high concentration of startups. Here’s a collection of the hottest biotech companies raising big cash in the Middle Eastern nation. Historically, Israel’s biotech industry has been viewed as secondary to its thriving medtech scene. However, in spite of a population of just 9 million people, the nation has […] September 21, 2022 - 6 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 21 Sep 2022 Collaboration will allow Evotec to evaluate small molecules developed by Adapsyn Chemical bioinformatics company, Adapsyn Bioscience Inc., and Evotec SE have entered into a strategic collaboration that will allow Evotec to have the opportunity to evaluate the small molecules developed by Adapsyn. Evotec will look at the molecules as potential therapeutic candidates in proprietary and partnered drug discovery projects. The news was announced today (September 21) […] September 21, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 20 Sep 2022 Biopharma company Faron announces escalation data cancer treatment study A clinical stage biopharma company has announced further dose escalation data from its phase 1/2 study looking at the safety and efficacy of a monotherapy in ten different hard-to-treat cancers. Latest progress from Faron Pharma’s MATINS (Macrophage Antibody To INhibit immune Suppression) study was focused on higher dose levels and frequencies to finalize the dose […] September 20, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 20 Sep 2022 Collaboration to develop new glioblastoma combination therapy nets €1.06M Dutch biotech CimCure B.V., French biotech company Covalab, Amsterdam UMC (The Netherlands) and the University of Zurich (Switzerland), have received a €1.06M ($1.08M) grant from EUREKA Eurostars. With a total budget of €2.24M ($2.28M), including investments from the partners, the project aims to develop a new treatment against glioblastoma. CimCure is the lead coordinator of […] September 20, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 19 Sep 2022 Global consortium looks to develop breakthrough RNA-based anti-cancer immunotherapy The Hadassah Cancer Research Institute (HCRI) at the Hadassah University Medical Center in Jerusalem, Israel, is to lead CanceRNA, a global consortium aiming to apply RNA-based therapeutics to successfully unlock anti-cancer immune responses. While RNA-based therapies, namely mRNA vaccines, shone during the pandemic and saved millions of lives, they have yet to be successfully tested […] September 19, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 19 Sep 2022 Tokyo scientists reveal possible new direction for getting rid of cancer cells Scientists from Tokyo University of Science have revealed how autophagy regulates the elimination of transformed cells that can initiate cancer. The elimination is necessary to maintain tissue integrity. The scientists have found that intact autograph vacuoles are indispensable in mediating competitive elimination of the cancer cells. They also noted perturbation of autophagy prevents cell […] September 19, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 19 Sep 2022 FDA boosts Antengene pancreatic cancer treatment Biopharma company Antengene Corporation Limited says ATG-101, the company’s in-house developed novel PD-L1/4-1BB bispecific antibody, has been granted an orphan drug designation (ODD) by the U.S. Food and Drug Administration (FDA) for the treatment of pancreatic cancer. The company said the ODD will help Antengene facilitate regulatory communication with the FDA, accelerate the clinical development […] September 19, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 19 Sep 2022 Bugworks Research and Cytecare Cancer Hospitals to set up cancer research center Bugworks Research Inc., a clinical stage biopharmaceutical company, and Cytecare Cancer Hospitals are set to collaborate by setting up a dedicated research center. Suresh Ramu, co-founder & CEO, Cytecare Cancer Hospitals, said: “We are excited to partner with Bugworks Research, in this inspiring endeavor to discover novel treatments for different types of cancers. In 2016, […] September 19, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 16 Sep 2022 Marengo advancing its lead TCR activator into clinic after FDA clearance Marengo Therapeutics is advancing its lead TCR activator, STAR0602, into clinic following clearance of its investigational new drug (IND) application by the U.S. Food and Drug Administration (FDA). STAR0602 is a bi-functional fusion antibody that deploys a mechanism of T cell activation that has demonstrated potent single agent activity in PD-1 refractory settings in preclinical […] September 16, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 16 Sep 2022 Ghana first to benefit from Roche partnership with Jhpiego to improve cervical and breast cancer outcomes for women Roche has signed a memorandum of understanding (MoU) with the Johns Hopkins Program for International Education in Gynecology and Obstetrics (Jhpiego) to improve cervical and breast cancer outcomes in resource-constrained countries. Breast cancer is the most diagnosed cancer and the cause of the most cancer-related deaths in women. Similarly, cervical cancer is the fourth most […] September 16, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email